Guest editorial
The Association for Molecular Pathology's Approach to Supporting a Global Agenda to Embrace Personalized Genomic Medicine

https://doi.org/10.1016/j.jmoldx.2011.03.001Get rights and content
Under a Creative Commons license
open access

Cited by (0)

1

Members of the Association for Molecular Pathology Whole Genome Analysis Working Group: Jane Gibson (Chair) (University of Central Florida College of Medicine, Orlando FL), Nazneen Aziz (College of American Pathologists, Northfield, IL), Pinar Bayrak-Toydemir (ARUP Laboratories, Salt Lake City, UT), Philip Cotter* (ResearchDx, Irvine CA), Daniel H. Farkas (Sequenom Center for Molecular Medicine, Grand Rapid, MI), Andrea Ferreira-Gonzalez (Virginia Commonwealth University, Richmond, VA), Manohar Furtado* (Life Technologies/Applied Biosystems, Foster City, CA), Timothy C. Greiner (University of Nebraska Medical Center, Omaha, NE), Tina Hambuch* (Illumina, Inc, San Diego, CA), Roger D. Klein (Blood Center of Wisconsin, Milwaukee, WI), Debra G.B. Leonard (Weill Cornell Medical College, New York, NY), Elaine Lyon* (ARUP Laboratories), Karen P. Mann (Emory University, Atlanta, GA), Rong Mao (ARUP Laboratories), Narasimhan Nagan* (Esoterix Genetic Laboratories, LLC, successor to Genzyme Genetics, Westborough, MA), Victoria M. Pratt* (Quest Diagnostics, Nichols Institute, Manassas, VA), Iris Schrijver (Stanford University School of Medicine, Stanford, CA), Mark E. Sobel (AMP Executive Officer, Bethesda, MD), Karl V. Voelkerding (University of Utah and ARUP Laboratories, Salt Lake City, UT), Mary Steele Williams (AMP Chief Operating Officer, Bethesda, MD).

*The following individuals disclosed relevant financial relationships: P.C. is employed by and owns stock in Illumina, Inc.; M.F. is employed by and owns stock in Life Technologies/Applied Biosystems; T.H. is employed by Illumina, Inc.; E.L. receives consulting fees from Novartis and Canon; N.N. is employed by Esoterix Genetic Laboratories, LLC, successor to Genzyme Genetics; V.P. is employed by and owns stock in Quest Diagnostics.

Genzyme Genetics is a trademark of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.